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Abstract 
The terms oral lichenoid reactions or oral lichenoid lesions refer to lesions histologically and clinically similar to 
oral lichen planus, though with the particularity that in these cases the underlying cause is identifiable. In addition, 
these lesions are described according to the causal factor involved, including alterations resulting from direct con-
tact with dental restoration materials, drug-related lesions, and lesions associated to graft-versus-host disease.
Drug-induced oral lichenoid reactions or oral lichenoid lesions were first cited in 1971 by Almeyda and Levantine. 
Since then, many drug substances have been associated with such lesions. The most common agents are nonsteroi-
dal antiinflammatory drugs and angiotensin converting enzyme inhibitors. 
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Drug groups Drug Reference No. cases Histology
Antihypertensive Methyldopa Stevenson (1971) 1 + ve
Methyldopa Burry&Kirk (1974) 3 2 + ve
1 - ve
Methyldopa Hay&Reade (1978) 17 8 + ve
2 - ve
9 no Bx
Methyldopa Brooks (1982) 1 No Bx
Methyldopa Williams (1983) 1 - ve
Oxprenolol Wiesenfeld et al. (1982) 1 + ve
Practolol Felix et al. (1974) 1 Not clear
Propanolol Hawk (1980) 1 + ve
Antimalarials Chloroquine Savage (1958) 1 No Bx
Pyrimethamine Cutler (1980) 1 + ve
Quinacrine Bagby (1945) 2 + ve
Quinacrine Nisbet (1945) Many Not registered
Quinacrine Schmitt et al. (1945) 16? Mostly + ve
Some no Bx
Quinacrine Bazemore et al. (1946) 150 None
Quinacrine Wilson (1946) >300 Some + ve
Some - ve
Some no Bx?
Ketoconazole Markitziu et al. (1986) 8 + ve
Antimicrobials Para-aminosalicylic 
acid
Shatin et al. (1953) 2 + ve
Tetracycline Fitzpatrick (1963) 1 No Bx
Sulfamethoxazole Bronny&Thies (1990) 1 Not clear
Fenclofenac Ferguson et al. (1984) 1 + ve
NSAIDs Phenylbutazone Gold (1966) 1 + ve
Nonspecific NSAID Potts et al. (1987) 27 Not clear
(Mostly Bx +ve)
Some - ve
Naproxen Gibson et al. (1986) 1 + ve
Rofecoxib Bagán et al. (2004) 3 No Bx
Tolbutamide Hurlbut (1963) 1 No Bx
Hypoglycemic drugs Chlorpropamide Dinsdale et al. (1968) 1 + ve
Penicillamine Penicillamine Seehafer et al. (1981) 6 4 + ve
2 no Bx
Penicillamine Powell et al. (1983) 11 7 + ve
2 - ve?
8 no Bx
Penicillamine Blasberg et al. (1984) 7 + ve
ACEIs Captopril, Enalapril Firth (1989) 2 Not clear
Thyrokinase-selective 
immuneosuppressors
Imatinib Pascual et al. (2006) 2 + ve
Imatinib Ena et al. (2004) 1 + ve
Imatinib Lim & Muir (2002) 1 + ve
Miscellaneous Allopurinol Chau et al. (1984) 3 1 + ve
2 no Bx
Amiphenazole Baker et al. (1964) 4 1 + ve
1 - ve
2 no Bx
Amiphenazole Dinsdale & Walker (1966) 1 + ve
Carbamazepine Roberts & Marks (1981) 1 + ve
Cyanamide Torrelo et al. (1990) 1 + ve
Levamisole Kirby et al. (1980) 2 + ve
Lithium Hogan et al. (1985) 1 + ve
Lithium Campisi et al. (2005) 1 + ve
Lorazepam Colvard et al. (1986) 1 - ve
Escitalopram Aframian (2007) 1 No Bx
Methopromazine Groth (1961) 1 + ve
Pyritinol Ishibashi et al. (1973) 1 + ve
Clopidrogel Guijarro (2003) 1 + ve
Adalimumab Simone et al. (2008) 1 + ve
Hepatitis B vaccine Pemberton (2000) 1 + ve
Interferon-alpha 2a, 
rivavicin, propanolol
Armour & Lowe (2005) 1 + ve
Interferon-alpha, ri-
vavicin
Giuliani (2008) 2 + ve
Table 1. Drugs reported in the literature as being related to oral lichenoid reactions. Expanded from the study of McCartan and McCreary 
(4) published in 1997 (Abbreviations: Bx = biopsy; +ve = positive; -ve = negative; ACEIs= angiotensin-converting enzyme inhibitors; 
NSAIDs= Nonsteroidal anti-inflammatory drugs).
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epoxy resins (composite) (1,7,8). 
Bäckman and Jontell (9) in turn have pointed to dental 
material coadjuvants such as dental tartar deposited upon 
the materials, oral breathing and hyposialia as etiologi-
cal factors. These authors published the case of a patient 
with all three factors who developed a lichenoid reaction 
in the absence of dental restoration. 
On the other hand, many drug substances are reportedly 
able to produce such reactions (Table 1). The most com-
monly implicated agents are nonsteroidal antiinflamma-
tory drugs and angiotensin converting enzyme inhibitors 
(10, 11).
In many cases these drugs are used in combination – thus 
suggesting the possible existence of synergic effects bet-
ween them. Some authors consider it quite likely that 
the so-called “Grinspan syndrome”, in which oral lichen 
planus is related to diabetes mellitus and arterial hyper-
tension, is in fact simply an example of oral lichenoid 
reaction induced by the drugs simultaneously used to 
treat the latter two diseases (12).
Clinical manifestations
The clinical manifestations of oral lichenoid lesions (Fig. 
1) are indistinguishable from those of oral lichen planus 
(7) – with mainly erythematous erosive lesions and an 
important ulcerative component. All these lesions are 
characterized by the presence of whitish streaks known 
as Wickham striae, similar to those seen in lichen planus 
(13). However, a very significant distinguishing factor 
with respect to OLP is their atypical location, and parti-
cularly the absence of bilaterality of the manifestations 
(2-6,9,13).
Concept
The terms oral lichenoid reactions (OLRs) or oral liche-
noid lesions (OLLs) refer to lesions histologically and 
clinically similar to oral lichen planus (OLP), though 
with the particularity that in these cases the underlying 
cause is identifiable (1).
The literature uses a range of different terms in reference 
to lesions of this kind (2). Most of the publications refer 
to them according to the causal factor involved, inclu-
ding alterations resulting from direct contact with dental 
restoration materials, drug-related lesions, and lesions 
associated to graft-versus-host disease (1,2).
Drug-induced oral lichenoid reactions were first men-
tioned in 1929, and were later cited in 1971 by Alme-
yda and Levantine (3). Many cases were documented 
among United States military personnel during the war 
in the Pacific, southeastern Europe and Indonesia. The 
mentioned authors reported an apparent relationship bet-
ween the clinical findings in these individuals and the 
prophylactic use of antimalarial drugs. Since then, many 
drug substances have been associated with such lesions 
(4).
Epidemiology
The precise epidemiological characteristics of these 
lesions are difficult to establish, due to the diverse and 
imprecise terminology used in establishing a final diag-
nosis of lichen planus (LP) as “probable”, “possible” or 
“suggestive”, in those situations where the histopatholo-
gical and clinical findings are less clear than in classical 
lichen planus (2). In addition, the absence of histological 
confirmation in most of the articles published on OLP-
related disorders makes it difficult to establish their true 
prevalence or incidence (5). 
Nevertheless, it is believed that the prevalence of OLRs 
attributable to drug substances is increasing. According 
to some authors (6), newly marketed drugs that are gene-
rally used among the population, such as antihypertensi-
ve agents, can cause such lesions as side effects. In con-
trast, other investigators point to increased experience 
and awareness among the different health professionals 
(dentists as well as dermatologists) as the factor contri-
buting to improved differentiation of the broad range of 
disorders related to lichen planus.
Etiopthogenesis
The etiopathogenic mechanism by which these lesions 
are produced is not known. The literature has identified 
a series of triggering factors, such as dental restoration 
materials, graft-versus-host disease, and a broad range 
of drugs (6,7).
A great many materials commonly used in restoration 
treatments in the oral cavity have been identified as tri-
ggering elements, including silver amalgam, gold, co-
balt, palladium, chromium and even non-metals such as 
Fig. 1. Image of a unilateral lichenoid reaction affecting the right 
cheek mucosa in a patient subjected to antihypertensive drug 
treatment. 
In relation to drug-induced lichenoid reactions, no spe-
cific clinical features have been described capable of fir-
mly differentiating them from lichenoid reactions cau-
sed by other factors. The only clue in this sense is an 
antecedent of recent or chronic exposure to some drug 
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Fig. 2. Image of a unilateral lichenoid reaction affecting the left 
cheek mucosa in direct relation to a ceramometallic crown.
substance. As a result, a differential diagnosis must be 
established, considering cases associated to the use of 
dental materials (Fig. 2), where the lesions are found in 
contact with or very close to the restorative materials, 
and confirming that the patient has no antecedents of 
graft-versus-host disease (6,7,14). 
Diagnosis
The diagnosis of OLRs is based on their clinical charac-
teristics and the histological findings (9,15). However, 
the sensitivity and specificity of histological diagnosis 
are very low (4). In addition, no definitive molecular 
diagnostic markers have been established to date (16). 
Van der Meij et al. (6) have proposed a modification of 
the diagnostic criteria of the World Health Organization 
for oral lichen planus and lichenoid reactions (Table 2).
As these are cause – effect lesions, the most precise 
diagnostic clue is determination of whether or not the le-
sions disappear after eliminating exposure to the suspect 
etiological factor (8).
However, in the case of drug-induced lesions, suspen-
sion of the medication may place patient health at risk 
(13). Furthermore, in many cases such measures are not 
useful and reliable as a diagnostic strategy, since the le-
sions may take months in resolving after suspending the 
suspect medication (3,17). 
Treatment
The management of such lesions first requires identi-
fication of the triggering factor, and the elimination of 
exposure to it. 
In the case of drug-induced OLRs, due evaluation of the 
risk / benefit ratio of suspending the medication is re-
quired. As has been commented, even if the causal me-
dication can be suspended, the lesions may take several 
Diagnostic criteria for oral lichen planus (OLP) and oral lichenoid lesions (OLLs)
Clinical criteria:
Bilateral presentation, more or less symmetrical lesions	
Presence of white striae (reticular pattern)	
Erosive, atrophic, bullous or plaque manifestations are only accepted as subtypes when always ac-	
companied by reticular lesions located anywhere in the mucosa.
The term “clinically compatible with” is to be used with all lesions similar to oral lichen planus that do not 
meet the mentioned criteria.
Histological criteria:
Well defined, mainly lymphocytic band infiltration in the most superficial zone of the connective tis-	
sue.
Signs of degenerative liquefaction in epithelial basal layer.	
Absence of epithelial dysplasia.	
The term “histologically compatible with” is to be used in application to all histopathological findings 
less clearly compliant with the mentioned criteria.
Final diagnosis of oral lichen planus and oral lichenoid lesions:
The clinical and histopathological criteria must be included in order to establish a final diagnosis. 
Both the clinical and histopathological criteria must be met in order to diagnose oral lichen planus. 
The term oral lichenoid lesions is to be used under the following conditions:
Clinically characteristic of oral lichen planus but histologically only “compatible with” oral lichen (1) 
planus
Histologically characteristic of oral lichen planus but clinically only “compatible with” oral lichen (2) 
planus
Both clinically and histologically “compatible wi(3) th” oral lichen planus.
Table 2. Modified World Health Organization criteria for the diagnosis of oral lichenoid reactions (OLRs), oral lichenoid lesions 
(OLLs) and oral lichen planus (OLP). Van de Meij et al. (6), 2007.
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months in improving. In addition, the pharmacological 
treatment of OLRs is often not feasible, because the long 
list of agents capable of causing such lesions includes 
many substances used to inhibit autoimmune T lympho-
cytes responses. These drugs are commonly used to treat 
very severe forms of lichen planus in its atrophic – ero-
sive presentation, and in particular include dapsone, le-
vamisole, tetracyclines and interferon (18,19).
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